AR096728A1 - Derivados de estratrieno-tiazol terapéuticamente activos - Google Patents
Derivados de estratrieno-tiazol terapéuticamente activosInfo
- Publication number
- AR096728A1 AR096728A1 ARP140102398A ARP140102398A AR096728A1 AR 096728 A1 AR096728 A1 AR 096728A1 AR P140102398 A ARP140102398 A AR P140102398A AR P140102398 A ARP140102398 A AR P140102398A AR 096728 A1 AR096728 A1 AR 096728A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- perhaloalkyl
- independently selected
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0063—Nitrogen and oxygen at position 2(3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a los compuestos de la fórmula (1) y sus sales farmacéuticamente aceptables. La presente se refiere asimismo a su utilización como inhibidores de 17b-HSD1 y en el tratamiento o la prevención de enfermedades o trastornos dependientes de las hormonas esteroides, tales como enfermedades o trastornos dependientes de las hormonas esteroides que requieren la inhibición de la enzima 17b-HSD1 y/o que requieren la disminución de la concentración de estradiol endógeno. La presente también se refiere a la preparación de los compuestos antes mencionados y a composiciones farmacéuticas que comprenden como ingrediente(s) activo(s) uno o más de los compuestos antes mencionados o sales farmacéuticamente aceptables de los mismos. Reivindicación 1: Un compuesto de fórmula (1) en donde (i) R¹ se selecciona del grupo integrado por H, NO₂, OH y N(R)₂; (ii-a) R² y R⁴ se seleccionan cada uno independientemente del grupo integrado por H, halógeno, alquilo-C₁₋₆, haloalquilo-C₁₋₃, perhaloalquilo-C₁₋₃, CN, NO₂, N₃, N(R)₂, (-CH₂)ₙN(R)₂, OR, (CH₂)ₙOR, CO₂R, CONHR, NHCOR, C(=NH)R, C(=N-OH)R y COR; y R³ se selecciona del grupo integrado por H, alquilo-C₁₋₆, haloalquilo-C₁₋₃, perhaloalquilo-C₁₋₆, N(R)₂, N₃ y OR³, en donde R³ se selecciona del grupo integrado por R, bencilo, succinilo, glucuronilo opcionalmente acilado, (CH₂)ₙOH, SO₂OH, SO₂R, tosilo, SO₂N(R)₂, PO(OR)₂, COOR, C(O)N(R)₂, C(O)(CH₂)ₙN(R)₂, C(O)CH₂NHC(O)R, C(O)CH₂NHC(O)OR y C(O)R; o (ii-b) R² y R³ o R³ y R⁴, junto con los átomos de carbono del anillo a los cuales están unidos, forman un anillo heterocíclico insaturado o aromático de 5 miembros que comprende 1 ó 2 heteroátomos, cada uno seleccionado independientemente de N y O, opcionalmente sustituido con metilo u oxo; y R⁴ o R², respectivamente, es H y halógeno; (iii) R⁵ y R⁶ se seleccionan cada uno independientemente del grupo integrado por H, halógeno,-OH, alcoxi-C₁₋₃ y CHO, o R⁵ y R⁶ forman juntos =CH-OH; R es H o alquilo-C₁₋₆, haloalquilo-C₁₋₃, o perhaloalquilo-C₁₋₃, o cuando es parte de algún N(R)₂, ambos R junto con el nitrógeno al cual están unidos pueden formar un anillo heterocíclico alifático o aromático de 5 a 6 miembros que comprende 1 ó 2 heteroátomos, cada uno seleccionado independientemente de N y O; R es alquilo-C₁₋₆, haloalquilo-C₁₋₃ o perhaloalquilo-C₁₋₃; R es alquilo-C₁₋₁₈, alquenilo-C₂₋₁₈, -(CH₂)ₙ-cicloalquilo-C₃₋₆, o fenilo opcionalmente sustituido; y n es 1 ó 2; o con la condición deque cuando R¹, R², R⁴, R⁵ y R⁶ son cada uno H, R³ no es OH o metoxi; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20135693 | 2013-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096728A1 true AR096728A1 (es) | 2016-01-27 |
Family
ID=51220583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102398A AR096728A1 (es) | 2013-06-25 | 2014-06-25 | Derivados de estratrieno-tiazol terapéuticamente activos |
Country Status (7)
Country | Link |
---|---|
US (1) | US10377791B2 (es) |
EP (1) | EP3013845B1 (es) |
JP (1) | JP6461127B2 (es) |
CN (1) | CN105518016B (es) |
AR (1) | AR096728A1 (es) |
TW (1) | TW201512215A (es) |
WO (1) | WO2014207309A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9320528B2 (en) * | 2013-06-26 | 2016-04-26 | Misonix, Incorporated | Ultrasonic cutting blade with cooling liquid conduction |
EP3237431B1 (en) | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | Prodrugs of 17.beta.-hsd1 -inhibitors |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
NZ760155A (en) * | 2017-06-08 | 2022-09-30 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5 |
EP3891167A1 (en) | 2018-12-05 | 2021-10-13 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2707999A (en) | 1998-03-11 | 1999-09-27 | Endorecherche Inc. | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
AU8838601A (en) | 2000-11-27 | 2002-06-03 | Entremed Inc | Antiangiogenic agents |
PL369108A1 (en) | 2001-09-06 | 2005-04-18 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
JP4309761B2 (ja) | 2001-10-17 | 2009-08-05 | シェーリング コーポレイション | アンドロゲン依存性疾患の治療を目的とする17βヒドロキシステロイドデヒドロゲナーゼ3型の阻害剤としてのピペリジンアセトアミンおよびピペラジンアセトアミン |
US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
PE20040750A1 (es) | 2002-11-18 | 2004-11-06 | Schering Corp | Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 |
US7053091B2 (en) | 2002-12-17 | 2006-05-30 | Schering Corporation | 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
WO2004085345A2 (en) | 2003-03-21 | 2004-10-07 | Yale University | 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
EP2125859B1 (en) | 2006-09-19 | 2013-05-15 | Abbott Products GmbH | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
CA2671075A1 (en) * | 2006-11-30 | 2008-06-05 | Solvay Pharmaceuticals Gmbh | Substituted estratrien derivatives as 17beta hsd inhibitors |
AU2012234682A1 (en) | 2011-03-25 | 2013-10-10 | Universite Laval | Inhibitors of 17beta-HSD1, 17beta-HSD3 and 17beta-HSD10 |
-
2014
- 2014-06-25 WO PCT/FI2014/050517 patent/WO2014207309A1/en active Application Filing
- 2014-06-25 US US14/392,289 patent/US10377791B2/en active Active
- 2014-06-25 TW TW103121873A patent/TW201512215A/zh unknown
- 2014-06-25 JP JP2016522678A patent/JP6461127B2/ja active Active
- 2014-06-25 AR ARP140102398A patent/AR096728A1/es unknown
- 2014-06-25 EP EP14742253.9A patent/EP3013845B1/en active Active
- 2014-06-25 CN CN201480046698.9A patent/CN105518016B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105518016A (zh) | 2016-04-20 |
JP6461127B2 (ja) | 2019-01-30 |
WO2014207309A1 (en) | 2014-12-31 |
TW201512215A (zh) | 2015-04-01 |
EP3013845A1 (en) | 2016-05-04 |
CN105518016B (zh) | 2020-10-23 |
US20170114090A1 (en) | 2017-04-27 |
US10377791B2 (en) | 2019-08-13 |
JP2016523885A (ja) | 2016-08-12 |
EP3013845B1 (en) | 2020-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096728A1 (es) | Derivados de estratrieno-tiazol terapéuticamente activos | |
CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
CL2018000666A1 (es) | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
AR096729A1 (es) | Derivados terapéuticamente activos de estratien-tiazol | |
AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
AR055105A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR106717A1 (es) | Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usos | |
AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
AR096727A1 (es) | Derivados terapéuticamente activos de estratrien-tiazol | |
AR110753A1 (es) | Inhibidores selectivos de jak1 | |
CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
AR080253A1 (es) | Inhibidores dimericos de las iap (proteinas inhibidoras de la apoptosis) | |
AR078537A1 (es) | Derivados heterociclicos de indol ligandos del receptor de estrogenos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades asociadas al sistema nervioso central, osteoporosis, canceres y otras patologias | |
AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |